The potential to harness the potency and specificity of the immune system underlies the
growing interest in cancer immunotherapy. One such approach uses bone marrow–derived …

The development of effective cancer vaccines depends heavily on the ability to deliver target
antigens to generate an immune response. Dendritic cells are the most potent antigen …

Dendritic cells (DC) are potent antigen presenting cells that are essential for the initiation of
primary immune responses. They richly express MHC, costimulatory and adhesion …

A novel approach to vaccination against cancer is to exploit dendritic cells (DCs) as 'nature's
adjuvants' and actively immunize cancer patients with a sample of their own DCs primed …

Mouse studies have shown that the immune system can reject tumours, and the
identification of tumour antigens that can be recognized by human T cells has facilitated the …

Cancer immunotherapy attempts to harness the power and specificity of the immune system
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …

Cancer immunotherapy aims at eliciting an immune response directed against tumor
antigens to help fight off residual tumor cells and thereby improve survival and quality of life …

Highlights•DC vaccines can induce anti-tumour responses and show clinical benefit.•DC
subsets specialised in Ag cross-presentation are key for anti-tumour responses.•Targeting …

The unique ability of dendritic cells to pick up antigens and to activate naive and memory
CD4+ and CD8+ T cells raised the possibility of using them to trigger a specific anti-tumor …

Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit.
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …